U.S. stock night market volatility: CG Oncology trial progress advanced, analysts raised target price, night market up 10.28%

U.S. Stock Night Market Movements CG Oncology rose 10.28% in the night market. Based on recent key news: On January 10, CG Oncology announced that the late-stage trial of its main asset cretostimogene grenadenorepvec is expected to produce top-line data in the first half of 2026, nearly a year earlier than previously planned. The accelerated trial enrollment led to an earlier timeline, driving the stock price up by about 31%. Source: Reuters On January 10, analyst Slutsky directly incorporated the medium-risk NMIBC opportunity into CG Oncology's valuation framework, raising its price target to $108 per share, reflecting a higher risk-adjusted value. Source: Bloomberg On January 10, analyst Roy pointed out that CG Oncology's enterprise value appears attractive relative to its risk-adjusted peak sales estimates, raising its price target from $75 to $85. Source: Morgan Stanley. The biopharmaceutical sector has recently performed strongly, with significant capital inflows. Stocks with High Trading Volume in the Industry Recursion rose 5.36% in the night market. Based on recent key news: On January 9, Blake Borgeson, a director of Recursion Pharmaceuticals, reported the sale of company common stock. This move may raise concerns in the market about insider confidence in the company, potentially affecting the stock price. On January 10, Recursion Pharmaceuticals submitted a preliminary beneficial ownership statement, listing Chief Scientific Officer David Hallett as a beneficial owner. This information may trigger market attention to the company's governance structure, impacting the stock price. On January 11, MarketBeat noted that Recursion Pharmaceuticals was not included in the list of five stocks recommended by top analysts. The hold rating from analysts on Recursion may lead to a cautious attitude from investors regarding its future performance. Market interest in biotech stocks has increased. MoonLake rose 9.84% in the night market. Based on recent key news: On January 10, several analysts raised their price targets for MoonLake, driving the stock price up. Analysts are optimistic about its future performance, believing that its upcoming BLA submission will have a positive impact, thus boosting the stock price. On January 9, the results of the meeting between MoonLake and the FDA indicated that no additional clinical trials are needed, enhancing market confidence. The FDA's recommendations have made MoonLake's BLA application process smoother, thereby uplifting the stock price On January 9th, analysts' rating adjustments for MoonLake reflect the market's optimism about its future potential. Analysts from BTIG and HC Wainwright & Co. have respectively raised and lowered their ratings, but the overall target price still shows optimistic expectations. The biotechnology industry has been active recently, with significant capital inflows. ZeZentalis Pharma rose 17.91% in after-hours trading. Based on recent key news: On January 10th, ZeZentalis Pharmaceuticals announced significant progress in the development plan for its main candidate drug azenosertib, including the completion of dose confirmation for DENALI Part 2a and an agreement with the FDA on the design of the ASPENOVA Phase 3 trial. These developments have enhanced market confidence in its Cyclin E1 positive indications, driving the stock price up. On January 9th, Walters Group and others reported acquisitions of common stock in ZeZentalis Pharmaceuticals, demonstrating investor confidence in the company's future development, further supporting the rise in stock price. On January 9th, Spark analysts maintained a neutral stance on ZNTL stock. Despite strong momentum supported by technical factors, the extremely overbought RSI has increased short-term risks. The company's updates have improved its outlook, with cash flow supporting operations until the end of 2027, ongoing trial progress, and strong stock performance. The biopharmaceutical industry has shown strong performance recently, with significant capital inflows